查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677327

疫苗病毒服务市场按服务类型、技术、应用和最终用户划分 - 2025 年至 2030 年全球预测

Vaccinia Virus Service Market by Service Type, Technology, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

疫苗病毒服务市场在2024年的价值为12.8亿美元，预计到2025年将达到13.5亿美元，预计年复合成长率为5.94%，到2030年将达到18.1亿美元。

主要市场统计数据
基准年 2024 年 12.8亿美元
预计 2025 年 13.5亿美元
预测年份 2030 18.1亿美元
复合年增长率（%） 5.94％

全球医疗保健领域的发展促使行业相关人员采用革命性的技术和创新方法，特别是在疫苗接种和基于病毒的应用领域。经过多年的历史使用和新兴的研究兴趣，痘苗病毒服务在分子医学和治疗发展方面取得了重大进展。本报告对痘苗病毒服务领域的现况、新兴趋势和策略机会进行了全面的分析。本报告深入探讨了市场动态，超越传统界限，评估了改变这一格局的科学、技术和临床因素。

在基因编辑、病毒复製过程和诊断应用的坚实基础的推动下，该领域有望加速成长。疫苗开发和临床前研究对复杂解决方案的需求日益增长，迫使供应商开发技术先进、经过临床检验的方法。本执行摘要是了解产业转型、细分洞察以及不断变化的区域和竞争动态的入口。

这里提出的分析是基于严格的方法和全面的资料综合。它不仅抓住了当前市场实践的精髓，而且还指明了未来创新和策略市场渗透的途径。透过根据多方面标准和区域影响力绘製详细的细分图，该研究强调了在不断变化的高级病毒服务格局中保持竞争力的综合方法的重要性。本介绍为更广泛地讨论这些动态因素如何影响基于痘苗病毒的应用的现在和未来奠定了基础。

此外，本研究提供的深度分析整合了来自各个子领域的见解，为专家和决策者提供了快速发展领域的技术清晰度和营运有效性。透过这篇深入的说明，读者将获得关键趋势和资料，为战略决策提供信息，确保在复杂、受监管和创新主导的环境中保持弹性并发挥竞争优势。

改变疫苗和病毒服务市场

痘苗病毒服务领域最近的转型转变正在引入创造性创新，有可能重塑既定范式并重新定义市场运作。次世代定序和重组 DNA 技术的整合正在提高病毒检测和表征的准确性和有效性，从而更深入地了解病毒行为和治疗潜力。

透过利用细胞培养技术的先进包装以及病毒包装和克隆方法的改进，服务供应商现在可以简化病毒复製和扩增过程，同时提高可靠性和扩充性。这些技术突破对于临床前和临床试验服务具有重要意义，因为严格的安全通讯协定和简化的操作程序至关重要。

学术研究与实用化的融合，带来了病毒载体工程的快速发展时代。基因编辑和基因工程开发能力的提高不仅加速了疫苗开发，而且有助于更广泛地了解宿主-病原体相互作用。这正在引发整个诊断和治疗领域的模式转移。相关人员越来越需要适应多层次的法律规范和快速发展的科学需求，这迫使他们不断重塑传统方法。

随着重组DNA技术的改进和病毒检测范式的优化，创新的实验模型正在成为主流。这些模型已成为完善市场策略和更准确预测结果的重要决策工具。因此，营运商正在重新考虑传统的伙伴关係，并与技术供应商和学术机构建立策略联盟，以降低风险并最大化成果。

以用户为中心的服务设计模式的兴起也推动了竞争格局的重塑，解决方案越来越多地根据製药公司、政府机构和专业研究机构的独特需求进行客製化。这种多样化也体现在利用先进细胞培养方法和创新病毒载体工程的协同效应的整合系统的部署。摘要，市场正在经历前所未有的变革，颠覆了长期存在的传统观念，并刺激了对研发的大量投资。

痘苗病毒服务市场的关键细分见解

痘苗病毒服务市场的細項分析为支持这个充满活力的行业的各个方面提供了重要见解。按服务类型细分显示，该市场得到了广泛的研究，包括基因编辑和工程（处于设计新治疗方法的前沿）以及临床前和临床试验服务（确保新型疫苗候选物的安全性和有效性）。此外，病毒复製和扩增服务以及先进的病毒测试和表征在确保产品品质和法规合规性方面发挥关键作用。业界对病毒生产服务的关注进一步凸显了在受控环境中扩大生产规模所需的技术力。

深入挖掘，基于技术的细分同样引人注目。细胞培养技术的应用仍然是该领域的基础，为病毒繁殖和治疗测试提供了基本平台。例如，次世代定序的创新透过提供详细的基因组见解有助于推动个人化医疗的发展。与此相辅相成的是病毒包装和克隆方法的进步，这些进步大大简化了建构高效病毒载体的过程。此外，病毒载体工程的进步正在成为增强治疗性介入介入的特异性和有效性的变革工具。

从应用角度来看，市场已从诊断、人类疫苗接种和研究等领域进行了分析。人类疫苗接种的进化轨迹以对猴痘和天花疫苗接种的专门研究为标誌，反映了对病毒感染疾病的防范以及与历史病原体相关的风险因素的復苏的战略重点。方面，研究应用，尤其是基因治疗研究和广泛的病毒学研究，对于阐明复杂的生物过程以及将实验室的发现转化为临床实践至关重要。如此多方面的细分不仅可以揭示明确的业务领域，还可以更深入地了解市场驱动因素和障碍。

最后一个细分观点是痘苗病毒服务的最终用户。这个市场正在受到政府机构、製药公司和研究机构的广泛研究。特别是在製药业，大企业和中小企业的差异凸显了业务规模、投资能力和研究重点的差异，进而影响市场趋势和创新週期。每个细分参数都强调了有针对性的策略的重要性，这些策略全面捕捉需求驱动因素和特定客户期望，并满足服务、技术、应用和最终用户维度上细微的市场需求。

总体而言，細項分析为理解推动痘苗病毒服务市场发展的多种因素提供了一个坚实的框架。这些竞争考察使相关人员能够有效地协调业务和策略重点，使他们在面对技术变革和竞争挑战时能够灵活应对。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 对客製化治疗和改善患者治疗效果的需求日益增长，推动了对标靶免疫疗法治疗的需求。
      • 大量政府资金和支持性法规结构正在刺激病毒载体技术的突破性研究并加速临床试验。
      • 全球意识的增强和对感染疾病预防的大量投入导致了痘苗病毒研究和开发活动的显着增加。
    • 限制因素
      • 勘探、开发和生产扩张高成本，影响盈利
    • 机会
      • 病毒载体在基因治疗、免疫治疗和疫苗传递系统的应用不断扩大
      • 生物製造流程和可扩展生产技术的持续进步将提高整体效率。
    • 任务
      • 不同司法管辖区的监管障碍和不断变化的合规要求
  • 市场区隔分析
    • 服务类型：精准病毒载体改造的基因编辑与工程服务
    • 最终用户：製药业扩张增加疫苗病毒服务需求
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

6. 疫苗病毒服务市场依服务类型划分

  • 基因编辑和工程
  • 临床前和临床试验服务
  • 病毒复製及扩增服务
  • 病毒检测与鑑定
  • 病毒製造服务

7 疫苗病毒服务市场（依技术）

  • 细胞培养技术
  • 次世代定序
  • 重组DNA技术
  • 病毒包装和克隆
  • 病毒载体工程

8. 疫苗病毒服务市场（依应用）

  • 诊断
  • 人类疫苗接种
    • 猴痘疫苗接种
    • 天花疫苗接种
  • 调查
    • 基因治疗研究
    • 病毒研究

9. 疫苗病毒服务市场（依最终用户划分）

  • 政府
  • 製药公司
    • 大型企业
    • 中小型企业
  • 研究组织

10. 美洲疫苗病毒服务市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太疫苗与病毒服务市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲疫苗和病毒服务市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • ABL Biomanufacturing
  • Batavia Biosciences
  • Creative Biogene
  • Creative Biolabs
  • Emergent BioSolutions
  • Helvetica Health Care
  • KBI Biopharma
  • Leinco Technologies
  • Lonza Group AG
  • Matica Biotechnology Inc.
  • Merck KGaA
  • Microchem Laboratory
  • Oxford Biomedica AG
  • Sino Biological
  • Thermo Fisher Scientific
  • Vaccinex
  • Virology Research Services
  • Virovek
  • ZeptoMetrix
Product Code: MRR-B02FEF845E5C

The Vaccinia Virus Service Market was valued at USD 1.28 billion in 2024 and is projected to grow to USD 1.35 billion in 2025, with a CAGR of 5.94%, reaching USD 1.81 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.28 billion
Estimated Year [2025] USD 1.35 billion
Forecast Year [2030] USD 1.81 billion
CAGR (%) 5.94%

The evolution of the global healthcare sector has prompted industry stakeholders to embrace revolutionary technologies and innovative approaches, particularly in the realm of immunizations and virus-based applications. With longstanding historical use and renewed research interest, vaccinia virus services are making significant inroads into molecular medicine and therapeutic development. This report introduces a comprehensive analysis of the current state, emerging trends, and strategic opportunities within the vaccinia virus service sector. It provides an in-depth exploration of market dynamics, moving beyond traditional boundaries to assess the scientific, technological, and clinical factors that are reshaping the landscape.

Driven by a robust foundation of gene editing, viral replication processes, and diagnostic applications, the sector is poised for accelerated growth. Amid increasing demands for sophisticated solutions in vaccine development and preclinical research, providers are compelled to develop technologically advanced and clinically validated methods. In this context, the executive summary serves as the gateway to understanding transformative industry shifts, segmentation insights, and evolving regional and competitive dynamics.

The analysis presented herein is informed by rigorous methodologies and comprehensive data synthesis. It not only captures the essence of current market practices but also identifies future avenues for innovation and strategic market penetration. By mapping out detailed segmentation based on multifaceted criteria and regional influences, the research underscores the importance of an integrated approach to staying competitive in the ever-changing landscape of advanced virus services. This introduction sets the stage for an extended discussion on how these dynamic factors collectively shape both the present and the future of vaccinia virus-based applications.

Furthermore, the depth of analysis provided in the study integrates insights from various sub-domains, offering experts and decision-makers technical clarity and operational effectiveness in a rapidly evolving field. Through this detailed exposition, readers will gain access to critical trends and data that inform strategic decisions, thereby ensuring resilience and leveraging competitive advantages in a complex, regulated, and innovation-driven environment.

Transformative Shifts in the Vaccinia Virus Service Landscape

Recent transformative shifts in the vaccinia virus service landscape are reshaping established paradigms and introducing disruptive innovations that hold the potential to redefine market operations. The integration of next-generation sequencing and recombinant DNA technologies is enhancing the precision and efficacy of viral testing and characterization, thereby providing deeper insights into virus behavior and therapeutic potential.

Capitalizing on advances in cell culture technology and the refinement of viral packaging and cloning methodologies, service providers are now able to streamline viral replication and amplification processes with increased reliability and scalability. These technological breakthroughs have profound implications for both preclinical and clinical trial services, where rigorous safety protocols and streamlined operational procedures are paramount.

The convergence of academic research and practical application has led to an era where viral vector engineering is experiencing rapid evolution. Enhanced capabilities in gene editing and engineering not only accelerate vaccine development but also contribute to a broader understanding of host-pathogen interactions. This in turn is triggering a paradigm shift across diagnostic and therapeutic sectors. Stakeholders are increasingly confronted with the need to adapt to multi-layered regulatory frameworks and rapidly evolving scientific demands, which require constant reinvention of conventional methodologies.

Innovative experimental models are becoming mainstream, driven by enhanced recombinant DNA technologies and the optimization of viral testing frameworks. These models serve as crucial decision-making tools that help refine market strategies and forecast outcomes with greater precision. As a result, operators are rethinking traditional partnerships, forging strategic alliances with technology suppliers and academic institutions to mitigate risk and maximize successful outcomes.

The realignment in the competitive environment is also being fueled by the proliferation of user-centric design in service delivery, where solutions are increasingly tailored to meet the unique needs of pharmaceutical companies, government agencies, and dedicated research institutes. This diversification is also evident in the deployment of integrated systems that leverage the synergy between advanced cell culture methods and innovative viral vector engineering. In summary, the market is witnessing an unprecedented impetus for change, challenging long-held norms and stimulating substantial investment in research and development.

Key Segmentation Insights in the Vaccinia Virus Service Market

The segmentation analysis of the vaccinia virus service market offers critical insights into the various dimensions that underpin this dynamic field. Examining segmentation by service type reveals that the market is extensively studied across gene editing and engineering, which is at the forefront of novel therapeutic design, as well as preclinical and clinical trial services that ensure the safety and efficacy of new vaccine candidates. In addition, viral replication and amplification services, alongside advanced viral testing and characterization, play a pivotal role in ensuring product quality and regulatory compliance. The industry's focus on virus production services further underscores the technical prowess required to scale up manufacturing in a controlled environment.

Delving deeper, segmentation based on technology is equally compelling. The application of cell culture technology remains a cornerstone of the field, providing a fundamental platform for virus propagation and therapeutic testing. Innovations in next-generation sequencing, for instance, are now instrumental in advancing personalized medicine by offering detailed genomic insights, while recombinant DNA technology underpins numerous breakthroughs in viral vector design. Complementary to these is the evolution of viral packaging and cloning methods which have significantly streamlined the process of constructing high-efficiency viral vectors. Furthermore, advancements in viral vector engineering are emerging as transformative tools that enhance the specificity and potency of therapeutic interventions.

From an application standpoint, the market is analyzed across diagnostic, human vaccination, and research domains. The evolutionary trajectory of human vaccination has been marked by specialized studies in both monkeypox and smallpox vaccination, reflecting a strategic emphasis on preparedness against viral outbreaks and the resurgence of risk factors linked to historical pathogens. On another front, research applications - particularly in gene therapy research and broader viral research - are vital to decode complex biological processes and facilitate the translation of laboratory findings into clinical practice. Such multifaceted segmentation not only illuminates distinct operational domains but also enables a more granular understanding of market drivers and barriers.

The final segmentation perspective centers on the end users of vaccinia virus services. The market is extensively explored through the lens of government agencies, pharmaceutical companies, and research institutes. Notably, within the pharmaceutical domain, differentiation between large enterprises and small and medium enterprises highlights varying operational scales, investment capacities, and research priorities, which in turn affect market trends and innovation cycles. Each segmentation parameter offers a comprehensive view of demand drivers and client-specific expectations, reinforcing the importance of targeted strategies that cater to nuanced market needs across service, technology, application, and end user dimensions.

Overall, the segmentation analysis provides a robust framework to understand the diverse components that drive the vaccinia virus service market. These insights enable stakeholders to tailor their operational and strategic priorities effectively, ensuring that they remain agile in the face of technological shifts and competitive challenges.

Based on Service Type, market is studied across Gene Editing & Engineering, Preclinical & Clinical Trial Services, Viral Replication & Amplification Services, Viral Testing & Characterization, and Virus Production Services.

Based on Technology, market is studied across Cell Culture Technology, Next-Generation Sequencing, Recombinant DNA Technology, Viral Packaging & Cloning, and Viral Vector Engineering.

Based on Application, market is studied across Diagnostic, Human Vaccination, and Research. The Human Vaccination is further studied across Monkeypox Vaccination and Smallpox Vaccination. The Research is further studied across Gene Therapy Research and Viral Research.

Based on End Users, market is studied across Government Agencies, Pharmaceutical Companies, and Research Institutes. The Pharmaceutical Companies is further studied across Large Enterprises and Small & Medium Enterprises.

Regional Dynamics Shaping the Global Vaccinia Virus Market

Insightful regional analysis reveals a diverse tapestry of influences across key geographic areas, each contributing uniquely to the evolution of the vaccinia virus market worldwide. The Americas, for example, continue to be a critical hub for advanced medical research and technological innovation. This region benefits from a strong network of academic institutions, leading pharmaceutical companies, and robust governmental support, which all contribute to the rapid adoption and integration of advanced virus services into clinical practice.

In the Europe, Middle East & Africa region, regulatory rigor and public health initiatives underscore the strategic emphasis on vaccine innovation and safety. The presence of mature biotechnology sectors, combined with dynamic research ecosystems, positions this region as both a conservative yet forward-thinking market. Stakeholders here benefit from stringent quality control measures, which ensure that products meet high safety standards essential in vaccine production and therapeutic applications.

The Asia-Pacific region is emerging as a powerhouse of growth and innovation within the space. Rapid technological adoption, coupled with significant government investment in health infrastructure, has paved the way for dynamic expansion in both research and commercial production environments. This region is witnessing a surge in collaborative ventures and strategic partnerships that seek to leverage localized technological expertise with global best practices. These evolving dynamics not only underscore the potential for exponential growth but also highlight the need for adaptive strategies that can navigate regional regulatory complexities and market-specific challenges.

Collectively, these regional insights emphasize the importance of understanding local market drivers and regulatory contexts. By comparing technological adoption rates and investment climates across such diverse regions, service providers can better align their strategies to meet local demands while capitalizing on global trends. The interplay between regional expertise, rigorous regulatory oversight, and technological innovation is shaping a landscape that prioritizes both quality and scale in vaccinia virus production and application.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Contributions in Vaccinia Virus Services

A comprehensive review of the competitive landscape unveils the critical roles played by key industry players in driving overall market growth and innovation within the vaccinia virus services realm. Firms such as ABL Biomanufacturing, Batavia Biosciences, and Creative Biogene have been instrumental in pioneering cutting-edge methodologies and establishing best practices. These organizations work in tandem with leaders like Creative Biolabs and Emergent BioSolutions, who bring forward robust pipelines and comprehensive research expertise that strengthen the industry's advancement.

Further, influential companies including Helvetica Health Care, KBI Biopharma, and Leinco Technologies continue to provide unmatched quality and scalability in virus production operations. Their combined efforts in research and development serve as the backbone of technical and operational excellence. The participation of global giants such as Lonza Group AG, Matica Biotechnology Inc., and Merck KGaA highlights an unwavering commitment to innovation that drives the efficient translation of scientific breakthroughs into real-world therapeutic solutions.

Equally noteworthy are the contributions of Microchem Laboratory and Oxford Biomedica AG, whose technical acumen and robust research frameworks underscore the critical importance of quality control and precision engineering in this space. Sino Biological, Thermo Fisher Scientific, and Vaccinex further bolster this dynamic environment by offering state-of-the-art technologies that enable advanced diagnostic and clinical applications. Specialized firms like Virology Research Services, Virovek, and ZeptoMetrix continue to set high benchmarks in operational efficiency and technical precision.

The competitive interplay among these firms demonstrates a vibrant ecosystem where collaboration and innovation are central to driving forward the boundaries of vaccinia virus research and application. Their combined expertise provides a roadmap for best practices in quality assurance, technological adoption, and global market penetration, thereby directly influencing the pace at which therapeutic and diagnostic solutions evolve within the sector.

The report delves into recent significant developments in the Vaccinia Virus Service Market, highlighting leading vendors and their innovative profiles. These include ABL Biomanufacturing, Batavia Biosciences, Creative Biogene, Creative Biolabs, Emergent BioSolutions, Helvetica Health Care, KBI Biopharma, Leinco Technologies, Lonza Group AG, Matica Biotechnology Inc., Merck KGaA, Microchem Laboratory, Oxford Biomedica AG, Sino Biological, Thermo Fisher Scientific, Vaccinex, Virology Research Services, Virovek, and ZeptoMetrix. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to continuously invest in research and development initiatives while maintaining robust partnerships with technological innovators to stay ahead in the competitive vaccinia virus services market. Companies should prioritize leveraging integrated technological platforms, as these not only streamline processes but also enhance overall production efficiency. Embracing advanced cell culture systems, recombinant DNA technologies, and next-generation sequencing methods can drive improved accuracy in efficacy testing and quality control.

It is advisable for leaders to design strategic roadmaps that incorporate a deep understanding of both micro and macro market forces. This can be achieved by aligning product development initiatives with evolving regulatory standards and emerging scientific trends. Companies should maintain a focus on scalability in their operations, ensuring that innovations in viral replication, amplification, and vector engineering are seamlessly transitioned from the research bench to clinical and market settings.

Leaders are also urged to adopt a flexible and adaptive approach, one that leverages detailed segmentation insights to customize solutions for distinct market segments such as human vaccination, diagnostic applications, and specialized research contexts. Recognizing the variable needs of government agencies, pharmaceutical giants, and research institutes is crucial for crafting targeted strategies that maximize market penetration while mitigating potential risks associated with regulatory or technological disruptions.

Lastly, fostering strategic collaborations and investing in cutting-edge infrastructure will be essential for maintaining a competitive edge. By championing a culture of innovation and operational excellence, industry leaders can not only meet current market demands but also set the stage for unforeseen future advancements. Strategic foresight, combined with a commitment to continual innovation, will safeguard long-term growth and development in the rapidly evolving vaccinia virus service landscape.

Conclusion: Embracing the Future of Vaccinia Virus Services

In summary, the vaccinia virus service market stands at a pivotal juncture, defined by rapid technological evolution, diverse market segmentation, and expanding regional dynamics. The current landscape is characterized by a convergence of groundbreaking innovations in gene editing, cell culture technology, and viral vector engineering, each contributing to enhanced operational efficiencies and better clinical outcomes. This in-depth analysis underscores how robust segmentation strategies, coupled with focused regional insights, are enabling stakeholders to realize significant progress across various application domains.

The dynamic interplay between technological advancements and market demands underscores an era rife with opportunity and challenges. As the industry continues to evolve, it is imperative that key players and innovators harness the potential of advanced technologies in order to drive sustainable growth. The emphasis on quality, scalability, and regulatory compliance remains central to the sector's long-term success.

Stakeholders who remain agile, informed, and proactive will be well-equipped to navigate the complexities of this emerging landscape. A strategic approach that incorporates detailed segmentation, leverages regional strengths, and fosters cross-industry collaborations will be critical to securing a competitive advantage. The insights provided in this report serve as a strategic compass, guiding industry executives toward informed decision-making and robust market positioning in a field undergoing continuous transformation.

Looking forward, the future of vaccinia virus services is poised to benefit from sustained investments in research, innovative production techniques, and collaborative ecosystems. Through such concerted efforts, companies and research institutions will be better positioned to respond to both current needs and future challenges, ensuring that innovation remains the cornerstone of progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for targeted immunotherapy treatment due to increasing need for customized therapies and improved patient outcomes
      • 5.1.1.2. Significant government funding and supportive regulatory frameworks fueling groundbreaking research and accelerating clinical trials in viral vector technology
      • 5.1.1.3. Rising global awareness and substantial investments in infectious disease prevention driving significant growth in vaccinia virus R&D activities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research, development, and production scaling hamper profitability
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding applications of viral vectors across gene therapy, immunotherapy, and vaccine delivery systems
      • 5.1.3.2. Continuous advancements in bio-manufacturing processes and scalable production techniques improving overall efficiency
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and evolving compliance requirements in various jurisdictions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Gene editing & engineering services tailored to achieve precise viral vector modifications
    • 5.2.2. End Users: Expansion of the pharmaceutical sector drives demand for vaccinia virus service
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccinia Virus Service Market, by Service Type

  • 6.1. Introduction
  • 6.2. Gene Editing & Engineering
  • 6.3. Preclinical & Clinical Trial Services
  • 6.4. Viral Replication & Amplification Services
  • 6.5. Viral Testing & Characterization
  • 6.6. Virus Production Services

7. Vaccinia Virus Service Market, by Technology

  • 7.1. Introduction
  • 7.2. Cell Culture Technology
  • 7.3. Next-Generation Sequencing
  • 7.4. Recombinant DNA Technology
  • 7.5. Viral Packaging & Cloning
  • 7.6. Viral Vector Engineering

8. Vaccinia Virus Service Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic
  • 8.3. Human Vaccination
    • 8.3.1. Monkeypox Vaccination
    • 8.3.2. Smallpox Vaccination
  • 8.4. Research
    • 8.4.1. Gene Therapy Research
    • 8.4.2. Viral Research

9. Vaccinia Virus Service Market, by End Users

  • 9.1. Introduction
  • 9.2. Government Agencies
  • 9.3. Pharmaceutical Companies
    • 9.3.1. Large Enterprises
    • 9.3.2. Small & Medium Enterprises
  • 9.4. Research Institutes

10. Americas Vaccinia Virus Service Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccinia Virus Service Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccinia Virus Service Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Matica Bio Partners with KaliVir
    • 13.3.2. Emergent biosolutions secures USD 400 million in contracts to boost vaccinia virus countermeasures and strengthen global biodefense preparedness
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Biomanufacturing
  • 2. Batavia Biosciences
  • 3. Creative Biogene
  • 4. Creative Biolabs
  • 5. Emergent BioSolutions
  • 6. Helvetica Health Care
  • 7. KBI Biopharma
  • 8. Leinco Technologies
  • 9. Lonza Group AG
  • 10. Matica Biotechnology Inc.
  • 11. Merck KGaA
  • 12. Microchem Laboratory
  • 13. Oxford Biomedica AG
  • 14. Sino Biological
  • 15. Thermo Fisher Scientific
  • 16. Vaccinex
  • 17. Virology Research Services
  • 18. Virovek
  • 19. ZeptoMetrix

LIST OF FIGURES

  • FIGURE 1. VACCINIA VIRUS SERVICE MARKET MULTI-CURRENCY
  • FIGURE 2. VACCINIA VIRUS SERVICE MARKET MULTI-LANGUAGE
  • FIGURE 3. VACCINIA VIRUS SERVICE MARKET RESEARCH PROCESS
  • FIGURE 4. VACCINIA VIRUS SERVICE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. VACCINIA VIRUS SERVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. VACCINIA VIRUS SERVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINIA VIRUS SERVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINIA VIRUS SERVICE MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GENE EDITING & ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PRECLINICAL & CLINICAL TRIAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL REPLICATION & AMPLIFICATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL TESTING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRUS PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL PACKAGING & CLONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL VECTOR ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY MONKEYPOX VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SMALLPOX VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GENE THERAPY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 327. VACCINIA VIRUS SERVICE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 328. VACCINIA VIRUS SERVICE MARKET, FPNV POSITIONING MATRIX, 2024